Neolpharma II

pending

 Grupo Neolpharma (“Neolpharma” or “the Group”) is a family-owned pharmaceutical company primarily operating in Mexico. It offers over 250 branded and generic medicines across various therapeutic areas, including central nervous system (CNS) diseases, cardiovascular diseases, oncology, and diabetes. In 2021, IFC financed Neolpharma’s initial expansion plan, encompassing the construction of a new injectables facility in Mexico City, the expansion of an active pharmaceutical ingredients (APIs) production plant in Ecatepec, Mexico, and other related expenditures (#39128). IFC is now proposing a new $70 million long-term corporate loan to support Neolpharma’s further expansion plan in Mexico (“the Project”). The Project includes (i) the acquisition, refurbishment, and reactivation of the NeolSym Civac API plant in Morelos (“API Plant”); (ii) the construction of a new injectables facility in Toluca to provide drug manufacturing services for a third party (“CMO Plant”); and (iii) technological upgrades and new equipment for Neolpharma’s existing plants, including the refurbishing of corporate offices.